Literature DB >> 17785583

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Stephanie J Lee1, John Klein, Michael Haagenson, Lee Ann Baxter-Lowe, Dennis L Confer, Mary Eapen, Marcelo Fernandez-Vina, Neal Flomenberg, Mary Horowitz, Carolyn K Hurley, Harriet Noreen, Machteld Oudshoorn, Effie Petersdorf, Michelle Setterholm, Stephen Spellman, Daniel Weisdorf, Thomas M Williams, Claudio Anasetti.   

Abstract

The relative importance of various human leukocyte antigen (HLA) loci and the resolution level at which they are matched has not been fully defined for unrelated donor transplantation. To address this question, National Marrow Donor Program data from 3857 transplantations performed from 1988 to 2003 in the United States were analyzed. Patient-donor pairs were fully typed for HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, and -DPA1 alleles. High-resolution DNA matching for HLA-A, -B, -C, and -DRB1 (8/8 match) was the minimum level of matching associated with the highest survival. A single mismatch detected by low- or high-resolution DNA testing at HLA-A, -B, -C or -DRB1 (7/8 match) was associated with higher mortality (relative risk, 1.25; 95% CI, 1.13-1.38; P < .001) and 1-year survival of 43% compared with 52% for 8/8 matched pairs. Single mismatches at HLA-B or HLA-C appear better tolerated than mismatches at HLA-A or HLA-DRB1. Mismatching at 2 or more loci compounded the risk. Mismatching at HLA-DP or -DQ loci and donor factors other than HLA type were not associated with survival. In multivariate modeling, patient age, race, disease stage, and cytomegalovirus status were as predictive of survival as donor HLA matching. High-resolution DNA matching for HLA-A, -B, -C, and -DRB1 alleles is associated with higher rates of survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785583     DOI: 10.1182/blood-2007-06-097386

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  406 in total

1.  Donor registries and search strategies.

Authors:  Carolyn K Hurley; Machteld Oudshoorn; Michelle Setterholm
Journal:  Methods Mol Biol       Date:  2012

2.  Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.

Authors:  Vikas Gupta; Martin S Tallman; Wensheng He; Brent R Logan; Edward Copelan; Robert Peter Gale; Hanna J Khoury; Thomas Klumpp; John Koreth; Hillard M Lazarus; David I Marks; Rodrigo Martino; David A Rizzieri; Jacob M Rowe; Mitchell Sabloff; Edmund K Waller; John F DiPersio; Donald W Bunjes; Daniel J Weisdorf
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

Review 3.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

4.  Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia.

Authors:  Mei-Jie Zhang; Stella M Davies; Bruce M Camitta; Brent Logan; Karin Tiedemann; Mary Eapen; Elizabeth L Thiel
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-06       Impact factor: 5.742

Review 5.  Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.

Authors:  Koen van Besien
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

6.  What Next? The Next Transit from Biology to Diagnostics: Next Generation Sequencing for Immunogenetics.

Authors:  Christian Gabriel; Stephanie Stabentheiner; Martin Danzer; Johannes Pröll
Journal:  Transfus Med Hemother       Date:  2011-09-25       Impact factor: 3.747

Review 7.  Prevention of graft-vs.-host disease.

Authors:  Andrew R Rezvani; Rainer F Storb
Journal:  Expert Opin Pharmacother       Date:  2012-07-07       Impact factor: 3.889

8.  Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.

Authors:  Yoshihiro Inamoto; Fumihiko Kimura; Junya Kanda; Junichi Sugita; Kazuhiro Ikegame; Hideki Nakasone; Yasuhito Nannya; Naoyuki Uchida; Takahiro Fukuda; Kosuke Yoshioka; Yukiyasu Ozawa; Ichiro Kawano; Yoshiko Atsuta; Koji Kato; Tatsuo Ichinohe; Masami Inoue; Takanori Teshima
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

9.  Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations.

Authors:  Yachiyo Kuwatsuka; Yoshiko Atsuta; Mary M Horowitz; Jiro Inagaki; Junya Kanda; Koji Kato; Katsuyoshi Koh; Mei-Jie Zhang; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-10       Impact factor: 5.742

10.  The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation - a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR.

Authors:  Julia Pingel; Tao Wang; Yvonne Hagenlocher; Camila J Hernández-Frederick; Arnon Nagler; Michael D Haagenson; Katharina Fleischhauer; Katharine C Hsu; Michael R Verneris; Stephanie J Lee; Mohamad Mohty; Emmanuelle Polge; Stephen R Spellman; Alexander H Schmidt; Jon J van Rood
Journal:  Bone Marrow Transplant       Date:  2018-10-02       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.